NeuroSense Therapeutics (NASDAQ:NRSN) and ALS-fighter, EverythingALS, are collaborating to identify treatments and a cure for ALS.
EverythingALS was founded in 2020 to bring tech innovations and data science in support of efforts for people with ALS. The non-profit conducts tech-based research to help track ALS progression so it can be used for clinical endpoints. All of the data and insights from research are made available as open science for researchers, pharma-companies and other potential partners.
“We are excited to be working with NeuroSense Therapeutics. EverythingALS and NeuroSense are taking similar actions in the fight against neurological diseases, including conducting extensive biomarker research. NeuroSense’s innovative therapeutic approach tackles this complex disease from multiple angles. Collaboration is key to making giant strides toward the digital biomarkers to be used in clinical trials of ALS, and to ultimately work toward the discovery of a potential cure,” said Indu Navar, founder of the Peter Cohen Foundation, functioning as EverythingALS.
Neurosense Therapeutics is a clinical-stage biotech company working on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The type of disease that Neurosense is built to chase cures for include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others. The company doesn’t exactly have its work cut out for it, either. These diseases, like all neurodegenerative diseases, are complex, but the company has strong scientific research on a large panel of related biomarkers. Now the company’s strategy involves developing combined therapies targeting multiple pathways associated with these diseases.
Specifically, ALS affects up to 30,000 people in the United States with 5,000 new cases every year, according to John Hopkins Medicine. ALS is a difficult disease from a diagnostic perspective because there isn’t a test or procedure to establish the diagnosis, and it can take from a year to a year-and-a-half to get an adequate diagnosis by way of elimination. Added to this is that there’s no known cure for ALS and any variety of treatment is only in clinical trial stage.
“At NeuroSense, our daily motivation stems from patients and their loved ones, resulting in a patient-centric approach to drug development. An alliance with EverythingALS, an organization with shared values, supports our mission to develop a disease-modifying therapy. Together, we aim to advance research on biological markers of the disease and deepen the scientific community’s knowledge of the underlying causes,” said Nedira Salzman-Frenkel, VP of business development at NeuroSense.
Towards this end, the company is busy enrolling patients in Phase IIb double blind, placebo controlled, multicenter clinical trial called PARADIGM, which will evaluate a drug candidate called PrimeC for ALS. Results are expected in Q2 2023.
PrimeC met its safety and efficacy benchmarks in its Phase IIa study, including reducing functional and respiratory deterioration and demonstrating statistically significant changes in ALS-related biological markers. Beyond the company’s ongoing research, Neurosense’s collaboration with EverythingALS will include a social component, where EverythingALS will provide insights into the needs of patients and give NeuroSense a chance to better serve the ALS community.
